Related references
Note: Only part of the references are listed.Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness
Peter Murphy et al.
MEDICAL DECISION MAKING (2021)
Creating historical controls using data from a previous line of treatment - Two non-standard approaches*
Anthony J. Hatswell et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2020)
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P. Solomon et al.
MODERN PATHOLOGY (2020)
A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability
Kei Fujikawa et al.
BIOMETRICAL JOURNAL (2020)
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement
Sarah P. Blagden et al.
BRITISH JOURNAL OF CANCER (2020)
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer
E. G. Elia et al.
CANCER EPIDEMIOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
Katy Cooper et al.
BRITISH JOURNAL OF CANCER (2020)
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib
Roberto Iezzi et al.
EUROPEAN RADIOLOGY (2019)
Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors
Hiroshi Imaoka et al.
ONCOLOGIST (2019)
The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer
Kentaro Ito et al.
LUNG CANCER (2019)
Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials
Jie Li et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Testing algorithm for identification of patients with TRK fusion cancer
Frederique Penault-Llorca et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
Susan J. Hsiao et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review
Stuart J. Wright et al.
PHARMACOECONOMICS (2019)
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
Mario J. N. M. Ouwens et al.
PHARMACOECONOMICS (2019)
Bivariate network meta-analysis for surrogate endpoint evaluation
Sylwia Bujkiewicz et al.
STATISTICS IN MEDICINE (2019)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
C. Marchio et al.
ANNALS OF ONCOLOGY (2019)
Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms
James P. Solomon et al.
CANCER RESEARCH (2019)
445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
D M Hyman et al.
ANNALS OF ONCOLOGY (2019)
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation
Kazuhiro Tanaka et al.
BMC CANCER (2019)
Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
Myung-Ju Ahn et al.
CANCER (2019)
Variance prior specification for a basket trial design using Bayesian hierarchical modeling
Kristen M. Cunanan et al.
CLINICAL TRIALS (2019)
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life
Stefania Morganti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Alyson Haslam et al.
EUROPEAN JOURNAL OF CANCER (2019)
Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials
Run-Cong Nie et al.
EUROPEAN JOURNAL OF CANCER (2019)
TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening
Catherine M. Albert et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials
Naveen Mangal et al.
HEMATOLOGICAL ONCOLOGY (2018)
Definitions and statistical properties of master protocols for personalized medicine in oncology
Lindsay A. Renfro et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2018)
New designs for basket clinical trials in oncology
Richard Simon
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2018)
ETV6-NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study
Christian Vokuhl et al.
PEDIATRIC BLOOD & CANCER (2018)
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Steven Coutre et al.
BLOOD (2018)
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
Liz Morrell et al.
BMC HEALTH SERVICES RESEARCH (2018)
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
Sirisha L. Mushti et al.
CLINICAL CANCER RESEARCH (2018)
A Bayesian basket trial design using a calibrated Bayesian hierarchical model
Yiyi Chu et al.
CLINICAL TRIALS (2018)
Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review
Marion Savina et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
Naveen Mangal et al.
HEMATOLOGICAL ONCOLOGY (2018)
Surrogate end points for overall survival in trials of PD-(L) 1 inhibitors for urinary cancers: a systematic review
Omar Abdel-Rahman
IMMUNOTHERAPY (2018)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity
Yiyi Chu et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS (2018)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones et al.
LANCET ONCOLOGY (2018)
Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment
Marta O. Soares et al.
MEDICAL DECISION MAKING (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bayesian basket trial design with exchangeability monitoring
Brian P. Hobbs et al.
STATISTICS IN MEDICINE (2018)
Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced NonSmall Cell Lung Cancer
Mahmoud Hashim et al.
VALUE IN HEALTH (2018)
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers A Systematic Review and Meta-analysis
Georgia Ritchie et al.
JAMA ONCOLOGY (2018)
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial
Sandra P. D'Angelo et al.
JAMA ONCOLOGY (2018)
Inhibiting TRK Proteins in Clinical Cancer Therapy
Allison M. Lange et al.
CANCERS (2018)
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
Howard L. Kaufman et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
Hannah L. Williams et al.
VIRCHOWS ARCHIV (2018)
LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
G D Demetri et al.
ANNALS OF ONCOLOGY (2018)
PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALS
C. Ling et al.
VALUE IN HEALTH (2018)
Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
Darren S. Sigal et al.
Oncotarget (2018)
Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials
Yanyang Pang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
Ryosuke Okamura et al.
JCO PRECISION ONCOLOGY (2018)
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples
L. A. Renfro et al.
ANNALS OF ONCOLOGY (2017)
Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy
Anthony J. Hatswell et al.
PHARMACOECONOMICS (2017)
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms
Hiroshi Imaoka et al.
ENDOCRINE-RELATED CANCER (2017)
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies
Giandomenico Roviello et al.
EUROPEAN JOURNAL OF CANCER (2017)
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer
Mohammed Kashif Siddiqui et al.
GYNECOLOGIC ONCOLOGY (2017)
Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs
Claire Rothery et al.
HEALTH ECONOMICS (2017)
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
Robert Hettle et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology
Yuri Sheikine et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives
David D. Kim et al.
MEDICAL DECISION MAKING (2017)
Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer
Giuseppe Colloca et al.
MEDICAL ONCOLOGY (2017)
Congenital mesoblastic nephroma 50 years after its recognition: A narrative review
S. L. Gooskens et al.
PEDIATRIC BLOOD & CANCER (2017)
An efficient basket trial design
Kristen M. Cunanan et al.
STATISTICS IN MEDICINE (2017)
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
Chiara Cremolini et al.
CANCER RESEARCH AND TREATMENT (2017)
Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials
Suresh K. Agarwal et al.
JOURNAL OF CANCER (2017)
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials A Meta-analysis
Gideon M. Blumenthal et al.
JAMA ONCOLOGY (2017)
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
A. Necchi et al.
ANNALS OF ONCOLOGY (2017)
Increasing the efficiency of oncology basket trials using a Bayesian approach
Rong Liu et al.
CONTEMPORARY CLINICAL TRIALS (2017)
Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials
Richard Simon
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
NTRK gene amplification in patients with metastatic cancer
Su Jin Lee et al.
PRECISION AND FUTURE MEDICINE (2017)
Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials
Eleftherios A. Makris et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia
Anthony J. Hatswell et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2017)
Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies
Rui Zhu et al.
AAPS JOURNAL (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
Marc Buyse et al.
BIOMETRICAL JOURNAL (2016)
Robust exchangeability designs for early phase clinical trials with multiple strata
Beat Neuenschwander et al.
PHARMACEUTICAL STATISTICS (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy
Toshikazu Moriwaki et al.
BRITISH JOURNAL OF CANCER (2016)
Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials
Liya Liu et al.
BULLETIN DU CANCER (2016)
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
Manju L. Prasad et al.
CANCER (2016)
Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer
Giuseppe Colloca et al.
CLINICAL COLORECTAL CANCER (2016)
Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer
Giuseppe Colloca et al.
CLINICAL GENITOURINARY CANCER (2016)
Analysis of Clinical End Points of Randomised Trials Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer
G. Colloca et al.
CLINICAL ONCOLOGY (2016)
Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker
R. A. Beckman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
Tsuyoshi Hamada et al.
EUROPEAN JOURNAL OF CANCER (2016)
Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting
Alona Zer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Rare Breast Cancer: 246 Invasive Secretory Carcinomas From the National Cancer Data Base
John Doromal Jacob et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma
Kentaro Nakashima et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies
Takehito Shukuya et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger et al.
LANCET ONCOLOGY (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer et al.
LANCET ONCOLOGY (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
Chul Kim et al.
MAYO CLINIC PROCEEDINGS (2016)
The Bayesian basket design for genomic variant-driven phase II trials
Richard Simon et al.
SEMINARS IN ONCOLOGY (2016)
A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions
Karl Claxton et al.
VALUE IN HEALTH (2016)
Colorectal adenocarcinoma: risks, prevention and diagnosis
Sri G. Thrumurthy et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Cancer Drugs Fund requires further reform
Richard Grieve et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Colorectal adenocarcinoma: risks, prevention and diagnosis
Sri G. Thrumurthy et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Cancer Drugs Fund requires further reform
Richard Grieve et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria
G. Heller
ANNALS OF ONCOLOGY (2015)
Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer
Oriana Ciani et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2015)
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Amanda J. Redig et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Gideon M. Blumenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
Ariel Lopez-Chavez et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The Rise in Appendiceal Cancer Incidence: 2000-2009
Schelomo Marmor et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample: A Fast, Nonparametric Regression-Based Method
Mark Strong et al.
MEDICAL DECISION MAKING (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics
Peter P. Luk et al.
PATHOLOGY (2015)
A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
Tessa Kennedy-Martin et al.
TRIALS (2015)
Biomarkers for the early diagnosis of hepatocellular carcinoma
Nobuhiro Tsuchiya et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials
Clemens Giessen et al.
ACTA ONCOLOGICA (2015)
Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review
Katsuyuki Hotta et al.
PLOS ONE (2015)
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model
Justyna M. Starczewska Amelio et al.
BMC CANCER (2014)
Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma
Neeraj Agarwal et al.
CLINICAL GENITOURINARY CANCER (2014)
Clinical Trial Design in Small Cell Lung Cancer: Surrogate End Points and Statistical Evolution
Myles Nickolich et al.
CLINICAL LUNG CANCER (2014)
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
Kohei Shitara et al.
GASTRIC CANCER (2014)
Mammary Analogue Secretory Carcinoma: Update on a New Diagnosis of Salivary Gland Malignancy
Roshan Sethi et al.
LARYNGOSCOPE (2014)
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
Kelong Han et al.
NEURO-ONCOLOGY (2014)
Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample: A Nonparametric Regression Approach
Mark Strong et al.
MEDICAL DECISION MAKING (2014)
The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis: Conceptual Framework and Application
Manuel A. Espinoza et al.
MEDICAL DECISION MAKING (2014)
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials
Fausto Petrelli et al.
MEDICAL ONCOLOGY (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials
Nicolas Penel et al.
BULLETIN DU CANCER (2014)
Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management
Yongzhi Wang et al.
CANCER LETTERS (2013)
Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
Roger Sidhu et al.
CLINICAL CANCER RESEARCH (2013)
Borrowing Information across Subgroups in Phase II Trials: Is It Useful?
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2013)
Surrogate End Points and Postprogression Survival in Renal Cell Carcinoma: An Analysis of First-Line Trials With Targeted Therapies
Fausto Petrelli et al.
CLINICAL GENITOURINARY CANCER (2013)
Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials
Scott M. Berry et al.
CLINICAL TRIALS (2013)
Melanoma incidence rises for children and adolescents: An epidemiologic review of pediatric melanoma in the United States
Mary T. Austin et al.
JOURNAL OF PEDIATRIC SURGERY (2013)
Borrowing Strength with Nonexchangeable Priors over Subpopulations
L. G. Leon-Novelo et al.
BIOMETRICS (2012)
Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the Surrogate Threshold Effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES)
Marissa N. Lassere et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Secretory carcinoma of the breast: Results from the survival, epidemiology and end results database
David P. Horowitz et al.
BREAST (2012)
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
T. E. Delea et al.
BRITISH JOURNAL OF CANCER (2012)
PHASE II CANCER CLINICAL TRIALS WITH HETEROGENEOUS PATIENT POPULATIONS
Sin-Ho Jung et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2012)
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib
Xiaoqin Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Biomarkers and surrogate endpoints in clinical trials
Thomas R. Fleming et al.
STATISTICS IN MEDICINE (2012)
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets
Cheryl Eifert et al.
NATURE REVIEWS CANCER (2012)
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
L. Lee et al.
ANNALS OF ONCOLOGY (2011)
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials
Nathan R. Foster et al.
CANCER (2011)
A Framework for Addressing Structural Uncertainty in Decision Models
Christopher H. Jackson et al.
MEDICAL DECISION MAKING (2011)
Model Averaging in the Presence of Structural Uncertainty about Treatment Effects: Influence on Treatment Decision and Expected Value of Information
Malcolm J. Price et al.
VALUE IN HEALTH (2011)
Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity
Alena Skalova et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
K. Tsujino et al.
ANNALS OF ONCOLOGY (2010)
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study
Peter G. Rose et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
Gini F. Fleming et al.
GYNECOLOGIC ONCOLOGY (2010)
Infantile Fibrosarcoma: Management Based on the European Experience
Daniel Orbach et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer
K. Hotta et al.
ANNALS OF ONCOLOGY (2009)
Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development
Tatiana Vidaurre et al.
CANCER JOURNAL (2009)
Progression-Free Survival Is Simply a Measure of a Drug's Effect While Administered and Is Not a Surrogate for Overall Survival
Julia Wilkerson et al.
CANCER JOURNAL (2009)
Multiple Histology Phase II Trials
Michael LeBlanc et al.
CLINICAL CANCER RESEARCH (2009)
The use of surrogate outcomes in mode-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports
R. S. Taylor et al.
HEALTH TECHNOLOGY ASSESSMENT (2009)
Use of surrogate outcomes in cost-effectiveness mode's: A review of United Kingdom health technology assessment reports
Julian Elston et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
Rashmi Chugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib
Kazuyuki Tsujino et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Michael C. Heinrich et al.
CLINICAL CANCER RESEARCH (2008)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Value of information on preference heterogeneity and individualized care
Anirban Basu et al.
MEDICAL DECISION MAKING (2007)
Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients
W. Ichikawa et al.
ANNALS OF ONCOLOGY (2006)
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
Kent R. Johnson et al.
LANCET ONCOLOGY (2006)
Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population
Ewa Brzezianska et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2006)
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
A Hackshaw et al.
BRITISH JOURNAL OF CANCER (2005)
One- and two-stage designs for stratified phase II clinical trials
WB London et al.
STATISTICS IN MEDICINE (2005)
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
P Bruzzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The value of information and optimal clinical trial design
AR Willan et al.
STATISTICS IN MEDICINE (2005)
R2WinBUGS: A package for running WinBUGS from R
S Sturtz et al.
JOURNAL OF STATISTICAL SOFTWARE (2005)
Expected value of sample information calculations in medical decision modeling
AE Ades et al.
MEDICAL DECISION MAKING (2004)
Cancer genes and the pathways they control
B Vogelstein et al.
NATURE MEDICINE (2004)
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
U Gatzemeier et al.
ANNALS OF ONCOLOGY (2004)
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma
N Makretsov et al.
GENES CHROMOSOMES & CANCER (2004)
Adaptive two-stage designs for single-arm phase IIA cancer clinical trials
Y Lin et al.
BIOMETRICS (2004)
Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria
D Coyle et al.
HEALTH ECONOMICS (2003)
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes
PF Thall et al.
STATISTICS IN MEDICINE (2003)
Bayesian two-stage designs for phase II clinical trials
SB Tan et al.
STATISTICS IN MEDICINE (2002)
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
M Buyse et al.
LANCET (2000)
Share Paper
